BR112015028551A2 - derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos - Google Patents

derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos

Info

Publication number
BR112015028551A2
BR112015028551A2 BR112015028551A BR112015028551A BR112015028551A2 BR 112015028551 A2 BR112015028551 A2 BR 112015028551A2 BR 112015028551 A BR112015028551 A BR 112015028551A BR 112015028551 A BR112015028551 A BR 112015028551A BR 112015028551 A2 BR112015028551 A2 BR 112015028551A2
Authority
BR
Brazil
Prior art keywords
pyrimidin
oxy
indol
methyl
relates
Prior art date
Application number
BR112015028551A
Other languages
English (en)
Inventor
Nufer Robert
Glaenzel Ulrike
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015028551A2 publication Critical patent/BR112015028551A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a b s t r a c t this invention relates to certain metabolites of n-(1-methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide in particular, the present invention relates to pharmaceutical compositions comprising these metabolites, as well as processes for their preparation and their use in the treatment of diseases. tradução do resumo resumo patente de invenção: "derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos". a presente invenção refere-se a certos metabolitos de n-(1-metil-5-(trifluorometil)-1h-pirazol-3-il)-5-((6-((metilamino)metil)pirimidin-4-yl)oxy)-1h-indol-1-carboxamida. em particular, a presente invenção refere-se a composições farmacêuticas compreendendo estes metabolitos, bem como processos para a sua preparação e ao seu uso no tratamento de doenças.
BR112015028551A 2013-05-17 2014-05-16 derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos BR112015028551A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824464P 2013-05-17 2013-05-17
PCT/IB2014/061484 WO2014184778A1 (en) 2013-05-17 2014-05-16 Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof

Publications (1)

Publication Number Publication Date
BR112015028551A2 true BR112015028551A2 (pt) 2017-07-25

Family

ID=50896374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028551A BR112015028551A2 (pt) 2013-05-17 2014-05-16 derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos

Country Status (13)

Country Link
US (2) US20150018376A1 (pt)
EP (1) EP2997022B1 (pt)
JP (1) JP2016518443A (pt)
KR (1) KR20160010522A (pt)
CN (1) CN105452241B (pt)
AR (1) AR096322A1 (pt)
AU (1) AU2014266867B2 (pt)
BR (1) BR112015028551A2 (pt)
CA (1) CA2912130A1 (pt)
EA (1) EA201592190A1 (pt)
ES (1) ES2699776T3 (pt)
MX (1) MX2015015845A (pt)
WO (1) WO2014184778A1 (pt)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
EP0938597B1 (en) 1996-09-06 2003-08-20 Obducat Aktiebolag Method for anisotropic etching of structures in conducting materials
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
JP4662635B2 (ja) 1998-11-20 2011-03-30 コーサン バイオサイエンシーズ, インコーポレイテッド エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
KR100371449B1 (ko) 1999-07-20 2003-02-07 주식회사 아이디어파크 무선 이어폰/마이크를 갖는 착탈형 무선전환장치
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JO3265B1 (ar) * 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Also Published As

Publication number Publication date
CA2912130A1 (en) 2014-11-20
ES2699776T3 (es) 2019-02-12
MX2015015845A (es) 2016-06-29
EP2997022A1 (en) 2016-03-23
CN105452241A (zh) 2016-03-30
KR20160010522A (ko) 2016-01-27
EA201592190A1 (ru) 2016-04-29
EP2997022B1 (en) 2018-08-29
AU2014266867A1 (en) 2015-12-03
AU2014266867B2 (en) 2017-07-13
AR096322A1 (es) 2015-12-23
CN105452241B (zh) 2018-01-05
WO2014184778A1 (en) 2014-11-20
US20150018376A1 (en) 2015-01-15
US9604969B2 (en) 2017-03-28
US20160115156A1 (en) 2016-04-28
JP2016518443A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015032546A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
BR112015018168A2 (pt) inibidores de rock suaves
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
BR112013025001A2 (pt) derivados de pirazolo pirimidina
EA201691231A1 (ru) Фармацевтические лекарственные формы
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
EA201590752A1 (ru) Препараты производных пиримидиндиона
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
BR112015028551A2 (pt) derivados de pirimidin-4-il)óxi)-1h-indol-1-carboxamida e usos dos mesmos
BR112015008380A2 (pt) uso de um composto de pirazol[4,3-d]pirimidina tetrassubstituída para o tratamento de nefropatia diabética
DOP2016000078A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio
BR112015022000A8 (pt) preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]